论文部分内容阅读
目的探讨螺内酯联合卡维地洛治疗老年人难治性高血压的临床疗效及安全性。方法将195例老年难治性高血压患者随机分为3组;71例给予螺内酯联合卡维地洛治疗为联合用药组;63例给予螺内酯治疗为螺内酯组;61例给予卡维地洛治疗为卡维地洛组。观察3组疗效及不良反应并作对照研究。结果联合用药组疗效优于螺内酯组及卡维地洛组,螺内酯组与卡维地洛组疗效无显著差异。结论螺内酯联合卡维地洛治疗老年人难治性高血压效果显著,可有效控制血压、改善左心室重构,且不良反应较少,可以临床广为应用。
Objective To investigate the clinical efficacy and safety of spironolactone combined with carvedilol in the treatment of refractory hypertension in the elderly. Methods 195 elderly patients with refractory hypertension were randomly divided into three groups; 71 cases were treated with spironolactone combined with carvedilol in combination group; 63 cases treated with spironolactone treated with spironolactone group; 61 cases given carvedilol as Carvedilol group. The efficacy and adverse reactions of the three groups were observed and compared. Results The combination therapy group was better than spironolactone group and carvedilol group, spironolactone group and carvedilol group no significant difference. Conclusion Spironolactone combined with carvedilol treatment of refractory hypertension in the elderly significant effect, which can effectively control blood pressure and improve left ventricular remodeling, and fewer adverse reactions, can be widely used clinically.